JP2022552314A5 - - Google Patents
Info
- Publication number
- JP2022552314A5 JP2022552314A5 JP2022521958A JP2022521958A JP2022552314A5 JP 2022552314 A5 JP2022552314 A5 JP 2022552314A5 JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022552314 A5 JP2022552314 A5 JP 2022552314A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025063708A JP2025108510A (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916468P | 2019-10-17 | 2019-10-17 | |
| US62/916,468 | 2019-10-17 | ||
| PCT/US2020/054601 WO2021071962A1 (en) | 2019-10-07 | 2020-10-07 | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| USPCT/US2020/054601 | 2020-10-07 | ||
| PCT/US2020/056387 WO2021077117A1 (en) | 2019-10-17 | 2020-10-19 | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063708A Division JP2025108510A (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022552314A JP2022552314A (ja) | 2022-12-15 |
| JP2022552314A5 true JP2022552314A5 (https=) | 2023-10-27 |
| JPWO2021077117A5 JPWO2021077117A5 (https=) | 2023-10-27 |
| JP7664913B2 JP7664913B2 (ja) | 2025-04-18 |
Family
ID=75537569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521958A Active JP7664913B2 (ja) | 2019-10-17 | 2020-10-19 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
| JP2025063708A Pending JP2025108510A (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063708A Pending JP2025108510A (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240226293A9 (https=) |
| EP (1) | EP4045539A4 (https=) |
| JP (2) | JP7664913B2 (https=) |
| CN (1) | CN114901693A (https=) |
| WO (1) | WO2021077117A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| EP4352519A4 (en) * | 2021-05-20 | 2025-05-14 | Synteny Therapeutics, Inc. | GENOMIC SAFE HARBORS |
| JP2024542159A (ja) * | 2021-11-04 | 2024-11-13 | アーティバ バイオセラピューティクス インコーポレイテッド | Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置 |
| JP2024543024A (ja) * | 2021-11-08 | 2024-11-19 | フェイト セラピューティクス，インコーポレイティド | 操作されたエフェクター細胞及び固形腫瘍の広範な標的化を増強する方法 |
| CN116103239A (zh) * | 2021-11-11 | 2023-05-12 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| AU2023206330A1 (en) * | 2022-01-11 | 2024-08-22 | Celularity Inc. | Cleavage resistant cd16 constructs and uses thereof |
| EP4504914A4 (en) | 2022-04-08 | 2026-04-29 | Fate Therapeutics Inc | Cells having solid tumor targeting backbone and use thereof |
| CA3247010A1 (en) | 2022-04-08 | 2023-10-12 | Ono Pharmaceutical Co., Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING |
| CN120035658A (zh) * | 2022-12-27 | 2025-05-23 | 恺兴生命科技(上海)有限公司 | Nkg2d工程化细胞及其组合物 |
| CN116445414B (zh) * | 2023-03-03 | 2025-07-08 | 广州瑞臻再生医学科技有限公司 | 基因修饰多潜能干细胞衍生的增强型nk细胞的方法及其应用 |
| CN117285651B (zh) * | 2023-09-27 | 2025-06-06 | 中国医学科学院北京协和医院 | 靶向c-MET的嵌合抗原受体、CAR-M及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| CN113862292B (zh) * | 2015-01-29 | 2024-12-27 | 明尼苏达大学董事会 | 嵌合抗原受体、组合物以及方法 |
| JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3003152A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| WO2018132506A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| US20210015859A1 (en) * | 2017-12-08 | 2021-01-21 | Fate Therapeutics, Inc. | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| CA3083779A1 (en) * | 2017-12-22 | 2019-06-27 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
| JP7575271B2 (ja) * | 2018-03-29 | 2024-10-29 | フェイト セラピューティクス，インコーポレイテッド | 操作された免疫エフェクター細胞およびその使用 |
| KR20220165254A (ko) * | 2020-03-26 | 2022-12-14 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Cd28h 도메인을 함유하는 키메라 항원 수용체 및 그 사용 방법 |
-
2020
- 2020-10-19 EP EP20877752.4A patent/EP4045539A4/en active Pending
- 2020-10-19 JP JP2022521958A patent/JP7664913B2/ja active Active
- 2020-10-19 WO PCT/US2020/056387 patent/WO2021077117A1/en not_active Ceased
- 2020-10-19 CN CN202080090875.9A patent/CN114901693A/zh active Pending
- 2020-10-19 US US17/769,651 patent/US20240226293A9/en active Pending
-
2025
- 2025-04-08 JP JP2025063708A patent/JP2025108510A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023005462A2 (https=) | ||
| JP2022552314A5 (https=) | ||
| BR112023012656A2 (https=) | ||
| CL2026000307A1 (es) | Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este. | |
| BR112021014123A2 (https=) | ||
| BR112023009656A2 (https=) | ||
| BR112022009896A2 (https=) | ||
| CL2025004153A1 (es) | Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso. | |
| BR112021017747A2 (https=) | ||
| BR112022024743A2 (https=) | ||
| BR112022026905A2 (https=) | ||
| BR112023011738A2 (https=) | ||
| BR112023004146A2 (https=) | ||
| BR112023006729A2 (https=) | ||
| BR102021018859A2 (https=) | ||
| BR112023016292A2 (https=) | ||
| BR112023011539A2 (https=) | ||
| BR112023011610A2 (https=) | ||
| BR112023008976A2 (https=) | ||
| BR102021020147A2 (https=) | ||
| BR102021018926A2 (https=) | ||
| BR102021018167A2 (https=) | ||
| BR102021017576A2 (https=) | ||
| BR102021016837A2 (https=) | ||
| BR102021016551A2 (https=) |